Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
Nita A. Limdi, Larisa H. Cavallari, Craig R. Lee, William B. Hillegass, Ann Holmes, Todd C. Skaar, Maria Pisu, Chrisly Dillon, Amber L. Beitelshees, Philip E. Empey, Julio D. Duarte, Vakaramoko Diaby, Yan Gong, Julie A. Johnson, John A. Graves, Shawn Garbett, Zilu Zhou, Josh F. Peterson, on behalf of Implementing GeNomics In pracTicE (IGNITE) Network Pharmacogenetic Working Group (IGNITE-PGx)
Topics & Concepts
Acute coronary syndromePercutaneous coronary interventionMedicineClopidogrelCYP2C19CardiologyAspirinInternal medicinePercutaneousMyocardial infarctionMetabolismCytochrome P450Antiplatelet Therapy and Cardiovascular DiseasesHealth Systems, Economic Evaluations, Quality of LifeAtrial Fibrillation Management and Outcomes